Phase 2 N=83 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Takayasu's Arteritis · Giant Cell Arteritis
Primary: Primary Outcome - Relapse-free Survival (RFS) — 10; 14; 8; 10 Participants — p=0.049
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Tocilizumab for Patients With Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of Patients That Have Achieved Complete Remission of Disease — 17; 4 Participants — p=0.0301
N/A N=165 Validation of a Diagnostic Algorithm of Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of CDU False-positive Patients — 73; 63; 0; 29 Participants
Phase 2 N=15 Baricitinib in Relapsing Giant Cell Arteritis
Arteritis, Giant Cell
Primary: Adverse Events — 93 percentage of subjects
Phase 1 N=24 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
Giant Cell Arteritis
Primary: Maximum Serum Concentration (Cmax) of TCZ — 197; 178 ug/mL
Phase 2 N=20 Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Phase 4 N=30 Tocilizumab Plus a Short Prednisone Taper for GCA
Giant Cell Arteritis
Primary: Sustained Remission — 23 Participants
Phase 3 N=250 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
Giant Cell Arteritis
Primary: Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper) — 56.0; 53.1; 14.0…
N/A N=377 Assessment of Giant Cell Arteritis Medical Practices in France
Giant Cell Arteritis
Primary: Patient Journey : Physicians Who Referred the Patient — 171; 31; 21; 17 Participants
Phase 2 N=52 A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
Giant Cell Arteritis
Primary: Percentage of Participants in Sustained Remission Until Week 28 — 19; 6 Participants
N/A N=10 GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysm
Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…
Phase 2 N=33 Tocilizumab for Renal Graft Inflammation
Late Complication From Kidney Transplant
Primary: Change in Inflammation on Renal Allograft Biopsy From Baseline to 6 Months — 3; 10 Participants — p=0.033
Phase 2 N=10 Rilonacept to Improve Artery Function in Patients With Atherosclerosis
Coronary Artery Disease · Atherosclerosis · Inflammation
Primary: C-Reactive Protein (CRP) — 3.7; 4.6 mg/L
Phase 3 N=429 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
Giant Cell Arteritis (GCA)
Primary: Percentage of Participants Achieving Sustained Remission at Week 52 — 29.0; 41.1; 46.4 percentage of participants — p==0.0019
N/A N=82 Arterial Function and Atherosclerosis in Essential Thrombocythemia
Atherosclerosis
Primary: Carotid Artery Stiffness (Expressed by Beta-stiffness Index ) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From…
Phase 2 N=23 FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Safety of Low-dose FK-506 in PAH — 8; 18; 9; 22 number of AEs
Phase 2 N=24 Etanercept and Vascular Function in Psoriasis
PSORIASIS
Primary: Vascular Function as Measured by Brachial Artery Flow-mediated Dilation (FMD) — 9.71; 11.15 percentage of brachial artery diameter
Phase 3 N=143 PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease
Rheumatoid Arthritis
Primary: Brachial Artery Diameter Change From Baseline in Response to Reactive Hyperemia — 8.3; 9.43 % changes in diameter of artery
Phase 4 N=36 MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis · Cardiovascular Disease
Primary: Change in Global Coronary Flow Reserve (CFR) After 6 Months of Therapy With Tildrakizumab — -0.03 CFR Ratio
Phase 2 N=20 Study of Tocilizumab to Treat Polymyalgia Rheumatica
Polymyalgia Rheumatica (PMR)
Primary: Proportion of Patients in Disease Remission at Six Months From Trial Entry — 9; 0 Participants
Phase 4 N=63 Subclinical Cardiovascular Disease in Psoriatic Disease
Cardiovascular Diseases · Myocardial Infarction · Atherosclerotic Cardiovascular Disease
Primary: Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript — 8.6; 2.8 Fold Change
Phase 2 N=70 KPL-301 for Subjects With Giant Cell Arteritis
Giant Cell Arteritis
Primary: Time to Flare by Week 26 — NA; 25.1 weeks — p=0.0263
N/A N=125 Non-invasive Computer-Aided Phenotyping of Vasculopathy
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
Phase 4 N=91 Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Aortic Vascular Inflammation as Measured by FDG-PET/CT — 1.6615; 1.6333; 0.0143; 0.0655 target to background ratio (TBR) — p=0.3712
Phase 2 N=13 Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
Age-Related Macular Degeneration · Choroidal Neovascularization
Primary: Monthly Rates of Anti-VEGF (Vascular Endothelial Growth Factor) Injections — 0.42; 0.83; 0.34; 0.83 Injections per Month
Phase 2 N=22 Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
Kawasaki Disease
Primary: Number of Participants With Adverse Events — 2; 3; 13 participants
Phase 3 N=197 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Vasculitis · Wegener's Granulomatosis · Microscopic Polyangiitis
Primary: Disease Remission — 63; 52 Participants — p=<0.001
Phase 4 N=19 Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Cardiac Allograft Vasculopathy
Primary: Macitentan: Nitroglycerin (NTG) Luminal Dilation Ratio as Proportion of Vasomotor Tone Attributable to Endothelin-1 (ET-1) — 0.33; 0.30 ratio
Phase 2 N=261 Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial
Aneurysm
Primary: Difference in Z-score for Rank of Maximum Transverse Diameter (MTD) Regressed on Z-score at Baseline to Assess Growth in Abdominal Aortic Aneurysm MTD Determined by CT…
N/A N=1 Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab
Relapsing Polychondritis
Primary: Physician Global Assessment of Disease Activity — 21; 14; 12; 43 mm